AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 26 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A new investigation suggests erythropoietin accounts for at least some angiogenesis and growth in gynecological tumors.
The new finding confirms previous suspicions that erythropoietin and its receptor may contribute to the survival of malignant tumors by influencing capillary growth, according to Yoshiko Yasuda and colleagues at Kinki University School of Medicine in Osaka-Sayama, Japan.
Erythropoietin (EPO) stimulates the production of red blood cells. Researchers examined its effects on gynecological malignancies.
"To investigate the role of the EPO/EPO receptor pathway in these tumors, we injected mouse monoclonal antibody against erythropoietin or the soluble form of EPO receptor into blocks of tumor specimens and cultured the blocks," Yasuda and colleagues said.
Several hours later, researchers found that continuous injections of the monoclonal antibodies decreased the number of tumor cells and capillaries present. Additional evaluations of the treated cells showed they died via apoptosis induction (Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis, 2002;1797-1805).
...Source: HighBeam Research, Erythropoietin factors into growth of gynecological cancers.